MHE November 2020

November 27, 2020

Results of APOLLO and REACH3 trials are scheduled for presentation at the American Society of Hematology meeting next month are expected to garner attention.

November 27, 2020

Public health policies and treatment advances have made a difference.

November 26, 2020

The second of a two-part story on 10 takeaways about the telehealth boom. The COVID-19 pandemic has been a bumpy ride in the U.S., featuring one controversy after another. One of the few areas of agreement is that the widespread adoption of telehealth amid the pandemic has been, by and large, a positive development.

November 26, 2020

Applying lessons from behavioral economics, health systems are using “nudges” to influence the choices clinicians make.

November 25, 2020

The first of a two-part story on 10 takeaways about the telehealth boom. The COVID-19 pandemic has been a bumpy ride in the U.S., featuring one controversy after another. One of the few areas of agreement is that the widespread adoption of telehealth amid the pandemic has been, by and large, a positive development.

November 24, 2020

There’s some skepticism as programs to address social determinants of health proliferate. Some data are being collected.

November 24, 2020

Therapies that target lung cancer at the molecular level are proliferating — and so are the biomarkers for guiding their use.

November 23, 2020

In the early going, patients seeking the expensive, customized cancer treatments called CAR-T cell therapy had to go to an academic medical center. But that’s changing, as Duncan Allen, M.H.A., of the community cancer network OneOncology explains.

November 23, 2020

Health plans build strategies to ensure their beneficiaries have easy access to and receive vital immunizations.

November 20, 2020

Two newly approved antibody-drug conjugates and changes in radiation therapy lead the way.

November 19, 2020

The Trump administration’s push to get more Medicare Shared Savings Program (MSSP) ACOs to take on downside risk is having an effect, but there are still many nontakers.

November 19, 2020

There is growing recognition among healthcare providers and payers that disease prevalence is inextricably tied to social and environmental factors that impact health. In fact, clinical care accounts for an estimated 20% of health outcomes, while 80% are the result of social determinants of health (SDOH).

November 18, 2020

The United States usually doesn’t fare very well in international health comparisons. The country’s healthcare ranks among, if not the, most expensive. The outcomes, as measured by metrics such as life expectancy at birth, are not top tier, especially when the U.S. is compared to well-off countries in Europe and Asia.

November 18, 2020

Entresto (sacubitril-valsartan) didn’t get a lot of love from payers after it was approved in 2015 because of its expense and the crowded armamentarium for heart failure. But Entresto has since made its way into guidelines for reduced ejection fraction heart failure, sometimes called systolic heart failure.